MGO One Seven LLC Acquires 6,643 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

MGO One Seven LLC raised its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 123.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 12,037 shares of the biopharmaceutical company's stock after buying an additional 6,643 shares during the period. MGO One Seven LLC's holdings in Halozyme Therapeutics were worth $575,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Smartleaf Asset Management LLC raised its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Louisiana State Employees Retirement System grew its stake in shares of Halozyme Therapeutics by 0.6% during the 4th quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after acquiring an additional 200 shares during the period. CreativeOne Wealth LLC increased its holdings in Halozyme Therapeutics by 1.6% in the 4th quarter. CreativeOne Wealth LLC now owns 18,383 shares of the biopharmaceutical company's stock worth $879,000 after acquiring an additional 294 shares in the last quarter. State of New Jersey Common Pension Fund D raised its stake in Halozyme Therapeutics by 0.6% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company's stock worth $2,279,000 after acquiring an additional 302 shares during the period. Finally, Parkside Financial Bank & Trust lifted its holdings in Halozyme Therapeutics by 21.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $58.05, for a total transaction of $580,500.00. Following the transaction, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,697 shares of company stock valued at $1,558,052 in the last quarter. 2.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on HALO. Wells Fargo & Company decreased their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. HC Wainwright reissued a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a report on Friday, April 25th. Benchmark reiterated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $62.89.

Halozyme Therapeutics Trading Up 1.9 %

NASDAQ:HALO traded up $1.16 during mid-day trading on Friday, hitting $61.19. 1,098,414 shares of the stock traded hands, compared to its average volume of 1,443,747. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics, Inc. has a 52 week low of $40.19 and a 52 week high of $66.00. The stock has a market capitalization of $7.56 billion, a price-to-earnings ratio of 17.84, a PEG ratio of 0.42 and a beta of 1.26. The firm's 50 day moving average is $60.79 and its two-hundred day moving average is $55.39.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. On average, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.